Matches in SemOpenAlex for { <https://semopenalex.org/work/W3178394495> ?p ?o ?g. }
- W3178394495 endingPage "3008" @default.
- W3178394495 startingPage "2997" @default.
- W3178394495 abstract "Lenvatinib is a standard of care option in first-line therapy of advanced hepatocellular carcinoma (HCC). In the present study, we aim to identify, in patients with HCC treated with lenvatinib, a possible association between occurrence and grading of adverse events (AEs) and outcome.We performed a retrospective analysis of 606 Japanese and Italian patients treated with lenvatinib in first-line setting and investigated the possible correlation between the onset of AEs, toxicity grade (G) and outcome measures such as overall survival (OS) and progression-free survival (PFS).The appearance of arterial hypertension G ≥ 2 independently predicted prolonged OS [hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.46-0.93, P = .0188], whereas decreased appetite G ≥ 2 independently predicted decreased OS (HR 1.70, 95% CI 1.25-2.32, P = .0007) by multivariate analysis. Appearance of hand-foot skin reaction independently predicted prolonged PFS (HR 0.72, 95% CI 0.56-0.93, P = .0149), whereas decreased appetite G ≥ 2 predicted decreased PFS (HR 1.36, 95% CI 1.04-1.77, P = .0277).Our main findings are that the occurrence of arterial hypertension G ≥ 2 is a predictor of longer survival, whereas decreased appetite G ≥ 2 predicts for a poor prognosis. A careful management of AEs under lenvatinib treatment for HCC is required, to improve patients' quality of life, minimize the need for treatment discontinuation and achieve optimal outcome." @default.
- W3178394495 created "2021-07-19" @default.
- W3178394495 creator A5003571894 @default.
- W3178394495 creator A5007268728 @default.
- W3178394495 creator A5008593372 @default.
- W3178394495 creator A5009103376 @default.
- W3178394495 creator A5012513340 @default.
- W3178394495 creator A5013194037 @default.
- W3178394495 creator A5013902375 @default.
- W3178394495 creator A5015404124 @default.
- W3178394495 creator A5015534419 @default.
- W3178394495 creator A5017999006 @default.
- W3178394495 creator A5019332793 @default.
- W3178394495 creator A5020047441 @default.
- W3178394495 creator A5021212136 @default.
- W3178394495 creator A5022551435 @default.
- W3178394495 creator A5023165797 @default.
- W3178394495 creator A5023981784 @default.
- W3178394495 creator A5025980433 @default.
- W3178394495 creator A5026964230 @default.
- W3178394495 creator A5028697785 @default.
- W3178394495 creator A5032593836 @default.
- W3178394495 creator A5035134420 @default.
- W3178394495 creator A5035435527 @default.
- W3178394495 creator A5035561731 @default.
- W3178394495 creator A5037691579 @default.
- W3178394495 creator A5040159293 @default.
- W3178394495 creator A5040485741 @default.
- W3178394495 creator A5042028913 @default.
- W3178394495 creator A5043332769 @default.
- W3178394495 creator A5043762552 @default.
- W3178394495 creator A5047345098 @default.
- W3178394495 creator A5049568375 @default.
- W3178394495 creator A5049569407 @default.
- W3178394495 creator A5050706722 @default.
- W3178394495 creator A5050786916 @default.
- W3178394495 creator A5051447472 @default.
- W3178394495 creator A5051613962 @default.
- W3178394495 creator A5058514609 @default.
- W3178394495 creator A5059536902 @default.
- W3178394495 creator A5062272413 @default.
- W3178394495 creator A5064709438 @default.
- W3178394495 creator A5068214058 @default.
- W3178394495 creator A5072760293 @default.
- W3178394495 creator A5073095975 @default.
- W3178394495 creator A5073493755 @default.
- W3178394495 creator A5074219274 @default.
- W3178394495 creator A5079893085 @default.
- W3178394495 creator A5080709934 @default.
- W3178394495 creator A5084839932 @default.
- W3178394495 creator A5084975806 @default.
- W3178394495 creator A5085648916 @default.
- W3178394495 creator A5086789525 @default.
- W3178394495 creator A5087989451 @default.
- W3178394495 creator A5088307695 @default.
- W3178394495 creator A5090570708 @default.
- W3178394495 date "2021-07-22" @default.
- W3178394495 modified "2023-10-15" @default.
- W3178394495 title "Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib" @default.
- W3178394495 cites W1834228192 @default.
- W3178394495 cites W1971837077 @default.
- W3178394495 cites W2014277051 @default.
- W3178394495 cites W2027193267 @default.
- W3178394495 cites W2294314163 @default.
- W3178394495 cites W2314952680 @default.
- W3178394495 cites W2597555201 @default.
- W3178394495 cites W2785478816 @default.
- W3178394495 cites W2787358630 @default.
- W3178394495 cites W2801111216 @default.
- W3178394495 cites W2893115280 @default.
- W3178394495 cites W2905923080 @default.
- W3178394495 cites W2911690953 @default.
- W3178394495 cites W2914940499 @default.
- W3178394495 cites W2945004896 @default.
- W3178394495 cites W2945730831 @default.
- W3178394495 cites W2953756046 @default.
- W3178394495 cites W2982497080 @default.
- W3178394495 cites W2985556259 @default.
- W3178394495 cites W2989612811 @default.
- W3178394495 cites W2995953853 @default.
- W3178394495 cites W3003135415 @default.
- W3178394495 cites W3005582591 @default.
- W3178394495 cites W3007171814 @default.
- W3178394495 cites W3015552590 @default.
- W3178394495 cites W3017096042 @default.
- W3178394495 cites W3021050019 @default.
- W3178394495 cites W3025022288 @default.
- W3178394495 cites W3025742326 @default.
- W3178394495 cites W3036349946 @default.
- W3178394495 cites W3042091422 @default.
- W3178394495 cites W3045387409 @default.
- W3178394495 cites W3087245658 @default.
- W3178394495 cites W3089552331 @default.
- W3178394495 cites W3092039522 @default.
- W3178394495 cites W3094290717 @default.
- W3178394495 cites W3094354508 @default.
- W3178394495 cites W3094592787 @default.
- W3178394495 cites W3099576739 @default.